Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca : London stocks gain as AstraZeneca resumes vaccine trials

share with twitter share with LinkedIn share with facebook
09/14/2020 | 03:17am EDT

* FTSE 100 rises 0.6%, FTSE 250 up 0.3%

Sept 14 (Reuters) - UK shares rose on Monday as drugmaker AstraZeneca resumed trials of its COVID-19 vaccine, while Brexit fears simmered ahead of a parliament vote on a plan to break international law by breaching parts of the divorce treaty with the European Union.

The House of Commons will debate the Internal Market Bill, which the EU has demanded Prime Minister Boris Johnson scrap by the end of September. After the debate, lawmakers will decide if it should go to the next stage.

The blue-chip FTSE 100 rose 0.6% in early trading, with a 0.8% gain for AstraZeneca Plc among the top boosts to the index.

The drugmaker said over the weekend it had resumed British clinical trials of its COVID-19 vaccine, one of the most advanced in development, after getting the green light from safety watchdogs.

The mid-cap FTSE 250 added 0.3%, with Oxford BioMedica leading gains. (Reporting by Shashank Nayar in Bengaluru; Editing by Subhranshu Sahu)


Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.15% 7943 Delayed Quote.4.42%
OXFORD BIOMEDICA PLC 3.67% 819 Delayed Quote.26.98%
share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
12:16aTo Find a Coronavirus Vaccine, GlaxoSmithKline Is Bonding With Its Biggest Co..
DJ
10/23ASTRAZENECA : says its Oxford vaccine deal allows it to add up to 20% of manufac..
RE
10/23AstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to..
RE
10/23NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/23NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/23Health Care Up After Final Presidential Debate -- Health Care Roundup
DJ
10/23ASTRAZENECA : Covid-19 Vaccine Trial From AstraZeneca, Oxford Can Resume in U.S...
DJ
10/23ASTRAZENECA : Pivotal Studies of Covid-19 Vaccines From AstraZeneca, J&J Resumin..
DJ
10/23ASTRAZENECA : Says FDA Authorises Restart Of COVID-19 Vaccine Trial in U.S.
RE
10/23NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
Financials (USD)
Sales 2020 26 703 M - -
Net income 2020 3 074 M - -
Net Debt 2020 13 178 M - -
P/E ratio 2020 47,1x
Yield 2020 2,72%
Capitalization 136 B 136 B -
EV / Sales 2020 5,58x
EV / Sales 2021 4,86x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 118,27 $
Last Close Price 103,58 $
Spread / Highest target 50,1%
Spread / Average Target 14,2%
Spread / Lowest Target -36,3%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC4.42%135 994
JOHNSON & JOHNSON-0.43%382 391
ROCHE HOLDING AG-5.29%280 884
PFIZER INC.-2.55%212 162
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-16.78%185 999